 6. a. Chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks of the study entry 6 weeks if prior nitrosourea. Prior treatment with either dasatinib or temsirolimus but not both is allowed. At least 3 weeks must have elapsed from the last dose. b. Biologic therapy anti-neoplastic i. Must not have received oral tyrosine kinase inhibitors other than dasatinib or other similar agents within 3 weeks of the study entry and all toxicities must have resolved to Grade 2 prior to enrollment. ii. Must not have received Bevacizumab or other monoclonal antibody therapy within 4 weeks of study the entry. 